Current antiplatelet treatment strategy in patients with diabetes mellitus

Jung Hwa Jung, Udaya S. Tantry, Paul A. Gurbel, Young Hoon Jeong

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations

Abstract

Patients with diabetes mellitus (DM) have accelerated atherosclerosis with an increased risk for atherothrombotic cardiovascular complications. A state of high platelet reactivity and activation, hypercoagulability (prothrombotic state) and a subdued response to standard antiplatelet agents may explain high rate of adverse cardiovascular events in patients with DM. Several antithrombotic treatment strategies have been developed to control the prothrombotic state in patients with DM: dose modification of commonly used agents; use of potent agents; and addition of a third antithrombotic drug (triple therapy) to commonly prescribed dual antiplatelet therapy of aspirin and a P2Y12 inhibitor. The present review aims to provide an overview of the current knowledge on platelet abnormalities in patients with DM, focusing on the challenges and perspectives of antiplatelet treatment strategies in this population.

Original languageEnglish (US)
Pages (from-to)95-113
Number of pages19
JournalDiabetes and Metabolism Journal
Volume39
Issue number2
DOIs
StatePublished - 2015

Keywords

  • Aspirin
  • Atherothrombosis
  • Diabetes
  • P2Y12 inhibitor
  • Platelet

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Current antiplatelet treatment strategy in patients with diabetes mellitus'. Together they form a unique fingerprint.

Cite this